Suppr超能文献

相似文献

1
Management of older or unfit patients with acute myeloid leukemia.
Leukemia. 2015 Apr;29(4):770-5. doi: 10.1038/leu.2014.216. Epub 2014 Jul 9.
2
Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.
Am J Hematol. 2021 Apr 1;96(4):493-507. doi: 10.1002/ajh.26079. Epub 2021 Jan 12.
4
Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.
Curr Hematol Malig Rep. 2016 Dec;11(6):537-544. doi: 10.1007/s11899-016-0348-8.
5
Assessing eligibility for treatment in acute myeloid leukemia in 2023.
Expert Rev Hematol. 2023 Mar;16(3):181-190. doi: 10.1080/17474086.2023.2185603. Epub 2023 Mar 8.
6
Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.
Expert Opin Pharmacother. 2018 Jun;19(8):865-882. doi: 10.1080/14656566.2018.1465562. Epub 2018 Apr 26.
8
Should older adults with AML receive post-remission therapy?
Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):106-11. doi: 10.1016/j.beha.2015.10.007. Epub 2015 Oct 20.
9
Acute myeloid leukemia: 2013 update on risk-stratification and management.
Am J Hematol. 2013 Apr;88(4):318-27. doi: 10.1002/ajh.23404.

引用本文的文献

1
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed -Mutated or -Rearranged AML.
J Clin Oncol. 2025 Aug 10;43(23):2606-2615. doi: 10.1200/JCO-25-00914. Epub 2025 Jun 12.
3
Cost-effectiveness of Enasidenib versus conventional care for older patients with mutant refractory/relapsed AML.
Leuk Lymphoma. 2025 Mar;66(3):488-496. doi: 10.1080/10428194.2024.2426073. Epub 2024 Nov 19.
5
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia.
Cell Death Dis. 2024 Jun 12;15(6):413. doi: 10.1038/s41419-024-06810-7.
6
Research Strategy for the Development of a Quality-of-Life Decision-Making Model for Older Patients With Acute Myeloid Leukemia.
J Adv Pract Oncol. 2023 May;14(4):272-283. doi: 10.6004/jadpro.2023.14.4.2. Epub 2023 May 1.
7
High-expression of the innate-immune related gene UNC93B1 predicts inferior outcomes in acute myeloid leukemia.
Front Genet. 2023 Jan 18;14:1063227. doi: 10.3389/fgene.2023.1063227. eCollection 2023.
10
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Leuk Lymphoma. 2023 Jan;64(1):250-252. doi: 10.1080/10428194.2022.2131416. Epub 2022 Oct 13.

本文引用的文献

2
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
J Clin Oncol. 2013 Sep 20;31(27):3360-8. doi: 10.1200/JCO.2012.47.4874. Epub 2013 Aug 12.
3
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
Blood. 2013 Aug 22;122(8):1384-94. doi: 10.1182/blood-2013-04-496596. Epub 2013 Jul 9.
7
Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes.
Leuk Res. 2013 Sep;37(9):998-1003. doi: 10.1016/j.leukres.2013.05.013. Epub 2013 Jun 6.
9
Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia.
Blood. 2013 May 23;121(21):4287-94. doi: 10.1182/blood-2012-12-471680. Epub 2013 Apr 2.
10
Acute myeloid leukaemia in adults.
Lancet. 2013 Feb 9;381(9865):484-95. doi: 10.1016/S0140-6736(12)61727-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验